tiprankstipranks
Advertisement
Advertisement
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
PremiumCompany AnnouncementsCellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
2M ago
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
Premium
The Fly
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
2M ago
Cellectis initiated with an Overweight at Barclays
Premium
The Fly
Cellectis initiated with an Overweight at Barclays
2M ago
Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year
PremiumThe FlyCellectis reports Q1 adjusted EPS (16c) vs. (17c) last year
3M ago
Cellectis sees cash runway into 4Q27
Premium
The Fly
Cellectis sees cash runway into 4Q27
3M ago
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
Premium
Company Announcements
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
3M ago
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
PremiumCompany AnnouncementsCellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
4M ago
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
Premium
The Fly
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
4M ago
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
Premium
Company Announcements
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100